Home
HelpTest ID COGBL Chromosome Analysis, Hematologic Disorders, Children's Oncology Group Enrollment Testing, Blood
Ordering Guidance
This test is only performed on specimens from pediatric patients being considered for enrollment in a Children's Oncology Group (COG) protocol. For all other patients, order CHRHB / Chromosome Analysis, Hematologic Disorders, Blood.
For children in whom disease relapse or a secondary myeloid neoplasm is a concern and enrollment in a new COG protocol is being considered; order COGBM / Chromosome Analysis, Hematologic Disorders, Children's Oncology Group Enrollment Testing, Bone Marrow.
Consultation with personnel from the Genomics Laboratory is recommended when considering blood studies for hematologic disorders. Call 800-533-1710 and ask for the Cytogenetics Genetic Counselor on call.
Shipping Instructions
Advise Express Mail or equivalent if not on courier service.
Necessary Information
1. A reason for testing, a flow cytometry and/or a bone marrow pathology report, and a Children's Oncology Group (COG) registration number and protocol number should be submitted with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.
2. If a child has received an opposite sex bone marrow transplant prior to specimen collection for this protocol, note this information on the request.
Specimen Required
Specimen Type: Blood
Container/Tube:
Preferred: Yellow top (ACD)
Acceptable: Green top (sodium heparin) or lavender top (EDTA)
Specimen Volume: 6 mL
Collection Instructions: Invert several times to mix blood.
Useful For
Evaluation of pediatric blood specimens for chromosomal abnormalities associated with hematologic malignancies for diagnostic and prognostic purposes in patients being considered for enrollment in Children's Oncology Group clinical trials and research protocols
This test is not useful for congenital disorders.
Highlights
Cytogenetics testing is important for the diagnostic and prognostic classification of pediatric neoplasia, and it is a critical element for enrollment of children into clinical trials affiliated with the Children's Oncology Group (COG). For over 25 years the Mayo Clinic Genomics Laboratory has served as one of a select number of laboratories in the United States approved by the COG for the conventional chromosome analysis and fluorescence in situ hybridization analysis of pediatric bone marrow, peripheral blood, and tissue specimens.
All enrollment-required elements of cytogenetics testing will be electronically submitted by the Mayo Clinic Genomics laboratory within the guidelines of COG.
Testing Algorithm
This test is only performed on specimens from pediatric patients who are candidates for enrollment in Children's Oncology Group (COG) clinical trials and research protocols.
This test includes a charge for cell culture of fresh specimens and professional interpretation of results. Analysis charges will be incurred for total work performed, and generally include 2 banded karyograms and the analysis of 20 metaphase cells. If no metaphase cells are available for analysis, no analysis charges will be incurred. If additional analysis work is required, additional charges may be incurred.
If this test is ordered and the laboratory is informed that the patient is not on a COG protocol, this test will be canceled and automatically reordered as CHRHB / Chromosome Analysis, Hematologic Disorders, Blood.
Method Name
Cell Culture without Mitogens followed by Chromosome Analysis
Reporting Name
COG-Chromosomes, Hematologic, BloodSpecimen Type
Whole bloodSpecimen Minimum Volume
3 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole blood | Ambient (preferred) | ||
| Refrigerated | |||
Reference Values
An interpretative report will be provided.
Day(s) Performed
Monday through Friday
Report Available
9 to 11 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88237, 88291-Tissue culture for neoplastic disorders; bone marrow, blood, Interpretation and report
88264 w/ modifier 52-Chromosome analysis with less than 20 cells (if appropriate)
88264-Chromosome analysis with 20 to 25 cells (if appropriate)
88264, 88285-Chromosome analysis with greater than 25 cells (if appropriate)
88283-Additional specialized banding technique (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| COGBL | COG-Chromosomes, Hematologic, Blood | 62386-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 602315 | Result Summary | 50397-9 |
| 602316 | Interpretation | 69965-2 |
| 602317 | Result | 62356-1 |
| GC024 | Reason for Referral | 42349-1 |
| 602318 | Specimen | 31208-2 |
| 602319 | Source | 31208-2 |
| 602320 | Method | 85069-3 |
| 602321 | Banding Method | 62359-5 |
| 602322 | Additional Information | 48767-8 |
| 602323 | Released By | 18771-6 |
NY State Approved
YesReflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| ML20C | COG Metaphases, 1-19 | No, (Bill Only) | No |
| M25C | COG Metaphases, 20-25 | No, (Bill Only) | No |
| MG25C | COG Metaphases, >25 | No, (Bill Only) | No |
| _STAC | Ag-Nor/CBL Stain | No, (Bill Only) | No |
Forms
If not ordering electronically, complete, print, and send a Children's Oncology Group Test Request (T829) with the specimen.